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The study has set an important and complicated goal
– to verify the hypothesis that genetic polymorphisms are
associated with a predisposition to all malignancies. 
The article is attractive because of the thorough design,
involving a large number of cases and carefully matched
controls. The approach by dividing the whole group of
breast cancers into 20 subgroups by histological type,
grade, and receptor is original and interesting. As it is
applied with great care, the data indeed provide novel
information about the genetic basis of breast cancer
genesis and possibly provide evidence that different types
of breast cancer might have different pathogenesis. These
data could be helpful in further basic research on breast
tumorigenesis, highlighting genetic characteristics for each
type of breast cancer. The authors have also shown that
heterogeneity of breast cancer at the genetic level is as
diverse as the morphological picture, a fact that has to
be taken into account in future research design.
Comparison of frequencies of polymorphisms in
several genes between two groups (cancer patients and
controls) in an otherwise homogeneous population leads
the authors to several important, and fatalistic, statements:
• genetic components play a role in all cancers,
• environmental factors act effectively only on
predisposed persons.
Though the first conclusion seems to be acceptable
to a large extent intuitively, the data provided by the
authors do not strengthen this belief, at least for us.
Thus, 90.6% of cancer patients harboured at least one
of the studied markers. But the same is true for more
than 80% of the control group. Why in one group are
these low and medium penetrance genes considered
as factors leading to development of breast cancer (or
any cancer in general) and ignored in the other group?
What makes a difference between two carriers of e.g.
CHK2 mutation? Are there other, as yet unclear, genetic
components which increase the significance of this
mutation? Or maybe some environmental factors? The
authors have taken great pains to stratify the two
groups but have ignored any lifestyle aspects.
There is no doubt that mutation carriers in genes
involved in DNA repair can be affected by a hostile
environment more severely and accumulate a greater
number of somatic mutations. It is estimated that the TP53
gene is mutated in about 50% of cancers [1]. Should we
call such cancer sporadic, or is it genetically predetermined
now? Do the authors believe that persons not possessing
the listed (and some other) markers could smoke, be
obese and enjoy mutagens without being punished?
Taking into account the high rate of genetic
polymorphisms in the population, the aim of the study
– to verify the hypothesis that genetic polymorphisms
are associated with a predisposition to all malignancies
– is hardly achieved as the relative risk seems to be
small and thus other, possibly environmental factors
could easily have a greater impact on the outcome in
terms of tumour development. The results might reflect,
in fact, the genetic variability within the population.
According to the results, 9% of breast cancer cases
did not show any marker and 16.6% (162) of control
group women were free of any marker tested. The main
clinical consequence of the study in our opinion could be
the possibility to release “marker negative” women from
an unnecessary mammographic screening programme.
But to receive the ultimate verification of the hypothesis,
it will be necessary to perform a follow-up study on this
group of women and to wait some 30-40 years. Besides,
there is a great probability that during the next years
several more cancer predisposing candidate genes will
be discovered and it could easily lead to the situation that
at least one marker will be found in 100% of cases and
controls. If so, this study approach could be considered
as an important contribution to overall understanding
about tumorigenesis, but it is difficult to predict its
application in clinical practice in the near future.
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